AKAMAI TECHNOLOGIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AKAMAI TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $663.45M | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $621.40M | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $608.91M | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $609.24M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $616.12M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $584.07M | Mar 1, 2018 |
| FY2017 | Jun 30, 2016 | $572.14M | Mar 1, 2018 |
| FY2017 | Mar 31, 2016 | $567.73M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $579.16M | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $551.03M | Feb 28, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $452.03M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $504.92M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $547.63M | Feb 20, 2026 |
| FY2022 | Dec 31, 2022 | $128.76M | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $123.69M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $137.84M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $133.38M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $160.53M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $178.92M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $156.50M | Feb 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $566.94M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $533.41M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $637.34M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $676.27M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $783.15M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $658.53M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $548.92M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $362.50M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $314.29M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $466.51M | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $513.56M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $470.88M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $406.05M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $391.43M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $335.37M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $269.32M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $261.37M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $246.17M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $222.43M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $167.63M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.52B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.52B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.35B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $1.27B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $1.40B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.22B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.06B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.01B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $800.98M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $871.81M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $507.79M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $390.43M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $457.91M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $241.27M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $328.97M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $514.31M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $359.67M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $217.61M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $254.15M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $180.95M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.48B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $10.37B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $9.90B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $8.30B | Feb 28, 2024 |
| FY2022 | Sep 30, 2022 | $8.14B | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $8.23B | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $8.31B | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $8.14B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $7.76B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $7.01B | Feb 26, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.50B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $5.49B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $5.30B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $3.94B | Feb 28, 2024 |
| FY2022 | Sep 30, 2022 | $3.86B | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $3.92B | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $4.00B | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $3.61B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.51B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.35B | Feb 26, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.98B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $4.88B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $4.60B | Feb 20, 2026 |
| FY2025 | Dec 31, 2022 | $4.36B | Feb 20, 2026 |
| FY2022 | Sep 30, 2022 | $4.28B | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $4.31B | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $4.31B | Feb 28, 2023 |
| FY2024 | Dec 31, 2021 | $4.53B | Feb 24, 2025 |
| FY2023 | Dec 31, 2020 | $4.25B | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $3.66B | Feb 28, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.21B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.15B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $2.85B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $2.76B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $2.16B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.67B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.60B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.49B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.50B | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $1.23B | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.42B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.97B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $2.47B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.92B | Feb 28, 2024 |
| FY2022 | Sep 30, 2022 | $1.79B | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $1.67B | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $1.53B | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $1.26B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $605.05M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $48.00M | Feb 26, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $930.23M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $517.71M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $489.47M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $542.34M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $536.73M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $352.92M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $393.75M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.04B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $313.38M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $324.17M | Feb 28, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 20, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | 1 | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 20, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | 1 | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 144.71M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 150.03M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 151.23M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | 156.49M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 160.51M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 162.71M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 162.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 162.90M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 169.89M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 173.25M | Mar 1, 2018 |